Despite recent FDA approval of new therapies to treat lupus nephritis, most patients fail to achieve clinical remission with standard-of-care treatment. This emphasizes the need for a greater understanding of the pathophysiology of lupus nephritis, with the expectation that this knowledge will inform the development of effective, targeted therapies for lupus nephritis. To date, pre-clinical studies have typically used animal models to identify immune pathways driving disease, but these efforts have been plagued by limited correlation with clinical benefit in humans. For this reason, the ability to directly analyze human kidney tissue from lupus nephritis patients is of significant importance. We performed spatial transcriptomics of pediatric Class III and Class IV lupus nephritis using the CosMx Spatial Molecular Imager (Nanostring, Inc.). In the pilot phase of their study, they confirmed the accurate annotation of major kidney stromal and immune cell types, including rare cells such as podocytes that have been challenging to identify in single-cell RNA-Seq datasets.